23.18
1.13 (5.12%)
| Penutupan Terdahulu | 22.05 |
| Buka | 22.18 |
| Jumlah Dagangan | 1,773,754 |
| Purata Dagangan (3B) | 1,327,058 |
| Modal Pasaran | 2,868,027,392 |
| Harga / Jualan (P/S) | 10.19 |
| Harga / Buku (P/B) | 4.65 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | -277.30% |
| Margin Operasi (TTM) | -435.71% |
| EPS Cair (TTM) | -4.23 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -80.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.25% |
| Nisbah Semasa (MRQ) | 5.37 |
| Aliran Tunai Operasi (OCF TTM) | -300.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -174.00 M |
| Pulangan Atas Aset (ROA TTM) | -22.25% |
| Pulangan Atas Ekuiti (ROE TTM) | -63.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Arcus Biosciences, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.25 |
|
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 34.93% |
| % Dimiliki oleh Institusi | 64.97% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gilead Sciences, Inc. | 30 Sep 2025 | 31,424,760 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 49.00 (Leerink Partners, 111.39%) | Beli |
| Median | 30.00 (29.42%) | |
| Rendah | 20.00 (Morgan Stanley, -13.72%) | Pegang |
| Purata | 32.83 (41.63%) | |
| Jumlah | 4 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 22.36 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 05 Mar 2026 | 45.00 (94.13%) | Beli | 22.21 |
| HC Wainwright & Co. | 02 Mar 2026 | 32.00 (38.05%) | Beli | 23.94 |
| Leerink Partners | 02 Mar 2026 | 49.00 (111.39%) | Beli | 23.94 |
| Wells Fargo | 12 Feb 2026 | 23.00 (-0.78%) | Pegang | 19.96 |
| Goldman Sachs | 13 Jan 2026 | 28.00 (20.79%) | Beli | 22.74 |
| Morgan Stanley | 08 Jan 2026 | 20.00 (-13.72%) | Pegang | 21.35 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Jan 2026 | Pengumuman | Arcus Biosciences Announces New Employment Inducement Grants |
| 18 Dec 2025 | Pengumuman | Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |